Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-04-04
DOI
10.1002/ajh.25484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
- (2019) Gerwin Huls et al. BLOOD
- Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
- (2018) Chezi Ganzel et al. AMERICAN JOURNAL OF HEMATOLOGY
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
- (2018) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
- (2018) Felicitas Thol et al. BLOOD
- Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
- (2018) Tapan M. Kadia et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study
- (2017) Arnaud Pigneux et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2017) Bart L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials
- (2016) Armin Rashidi et al. BLOOD
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
- (2016) Farhad Ravandi et al. CANCER
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
- (2016) Gail J Roboz et al. Future Oncology
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
- (2016) Daisuke Araki et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
- (2016) W Blum et al. LEUKEMIA
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute myeloid leukemia-Major progress over four decades and glimpses into the future
- (2015) Hagop Kantarjian AMERICAN JOURNAL OF HEMATOLOGY
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- (2015) Iskra Pusic et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
- (2015) N. Boissel et al. HAEMATOLOGICA
- Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
- (2015) N. Boissel et al. HAEMATOLOGICA
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
- (2012) O. C. Goodyear et al. BLOOD
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
- (2011) H. F. Fernandez et al. BLOOD
- Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
- (2011) Christoph Röllig et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
- (2011) John R. Wingard et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
- (2010) Michael Grövdal et al. BRITISH JOURNAL OF HAEMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started